Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Dermatologic 1

Conditions

Small Cell Lung Carcinoma 1Sezary Syndrome 1Recurrence 1Mycosis Fungoides 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, T-Cell 1Lymphoma 1Immunoblastic Lymphadenopathy 1

Interventions

fludarabine phosphate 7Peripheral Blood Stem Cell Transplantation 7Cyclophosphamide 7Filgrastim 6Bortezomib 6tanespimycin 5Vorinostat 5Tacrolimus 5Radiotherapy 4Lenalidomide 4Gemcitabine 4fludarabine 3Whole-Body Irradiation 3Mycophenolic Acid 3Irinotecan 3Etoposide 3Dasatinib 3Bendamustine Hydrochloride 3romidepsin 2nelarabine 2laromustine 2entinostat 2devimistat 2bryostatin 1 2belinostat 2aldesleukin 2Vitamin B 12 2SUB1 protein, human 2Polymerase Chain Reaction 2Pharmacogenomic Testing 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Sezary Syndrome × MAC-ST-001 × Clear all
NCT04234048 2025-09-22

Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma

SciTech Development, Inc.

Phase 1 Recruiting
46 enrolled
DermatologicLymphoid

Immunoblastic Lymphadenopathy, Lymphoma, Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡